Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-120-9 | CAS number: 2634-33-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1988
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- Purity : 73.1%
PROXEL Press Paste
Reference ADH374793, Bx973 - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% aqueous polysorbate 80
- Doses:
- 0, 100, 300, 500 and 900 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 670 mg/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 490 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- There were no deaths in animals dosed with 100 or 300 mg/kg. One female dosed with 500 mg/kg was killed in extremis on Day 2. All the males and three females dosed with 900 mg/kg died or were killed in extremis on Days 1 or 2.
- Clinical signs:
- other: There were no signs of toxicity at any time in the animals dosed with 100 mg/kg. Signs of slight toxicity in those dosed with 300 mg/kg were piloerection and upward curvature of the spine, neither of which persisted after Day 3. Surviving animals dosed wi
- Gross pathology:
- There were no macroscopic abnormalities in any animal at necropsy.
- Conclusions:
- Materials and methods
Groups of five male and five female rats were given a single oral dose of 100, 300, 500 or 900 mg/kg of PROXEL press paste, as preparations in 5% (w/v) aqueous polysorbate 80. The animals were weighed and observed for fourteen days after dosing. PROXEL press paste (wet) is a 73.1% BIT technical grade material.
The methodology employed was equivalent to those described in guidelines OECD401, EC B.1.
Results and discussion There were no deaths and no signs of toxicity at 100 mg/kg and no deaths but signs of slight toxicity at 300 mg/kg. One female dosed with 500 mg/kg was killed in extremis and there were signs of slight toxicity in the survivors. Following dosing with 900 mg/kg there were signs of marked toxicity and all the males and three females died or were killed in extremis on Days 1 or 2. There were no macroscopic abnormalities in any animal at necropsy.
The acute oral median lethal dose value was 670 mg/kg (approximate 95% confidence limits 500, 900) to male rats and 784 mg/kg (lower 95% confidence limit 475) to female rats. - Executive summary:
A study was conducted to determine the acute oral toxicity of the substance according to a method similar to OECD Guideline 401. Groups of five male and five female rats were administered a single oral dose of 0, 100, 300, 500 or 900 mg/kg bw of the substance in a 0.5% (w/v) aqueous polysorbate 80 suspension. The animals were weighed and observed for fourteen days after dosing. There was no mortality at 100 and 300 mg/kg. One female at 500 mg/kg bw was sacrificed in extremis. At 900 mg/kg bw there were signs of marked toxicity and all the males and three females died or were sacrificed in extremis on Day 1 or 2. There were no macroscopic abnormalities in any animal at necropsy. Under the study conditions, the acute oral LD50 of the substance was determined to be 670 mg/kg bw (490 mg a.i./kg bw) in rats (Leah, 1988).
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1994
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- yes
- Specific details on test material used for the study:
- Batch No. GK 100 B
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- other: T52-003:Aqueous 0.5% w/v methylcellulose
- Doses:
- 0, 202, 320 and 506 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- Only male animals were tested at the three dose levels. Females were included at the lowest dose level to show that females were not more sensitive than male animals.
- Statistics:
- Probit analysis by the method of Finney (1971) was used to determine the acute median lethal dosage, 95% confidence interval and slope of the dose response curve of the test material.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 454 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Two male animals treated at 506 mg/kg died within the first hour after dosing and another animal was found dead two hours later. One animal treated at 320 mg/kg died during the first overnight period.
There was no death at the low dosage of 202 mg/kg. - Clinical signs:
- other: Ante mortem signs comprised lethargy, underactivity, staggering gait, prone position, pallor, hyperpnoea, piloerection, hunched posture and pupil dilation. Signs of reaction to treatment in the surviving animals in all dose levels included underactivity,
- Gross pathology:
- Necropsy findings for the decedents were unremarkable.
Necropsy of the surviving animals, on Day 15, revealed no significant macroscopic lesion. - Conclusions:
Materials and methods
Young adult rats (CD strain, remote Sprague-Dawley origin) were held in a limited-access facility kept at slight positive pressure relative to the outside. Target values for temperature and humidity were 21°C (range 19O-25°C) and 55% R.H. (range 40%-70% R.H.), respectively. A commercially-available complete pelleted rodent diet was fed ad libitum.
The main study was carried out using three groups of five male rats (one group at each concentration level) and one group of five female rats (at the lowest dose level). Each group was given a single oral administration of BIT at dosages of 202, 320 or 506 mg/kg, at a constant volume-dosage of 20 mL/kg in aqueous 0.5% w/v methylcellulose.
Animals were inspected regularly and the bodyweight of each animal was recorded on the day before dosing and on Days 1, 8 and 15. The test was terminated on the morning of Day 15.
All animals were examined for abnormality of tissues or organs. All body cavities were opened, larger organs were sectioned and the gastro-intestinal tract was opened at intervals for examination of the mucosal surfaces. All abnormalities were described or the normal appearance of major organs was confirmed.
The methodology employed was as described in guidelines OECD401, EC B.1.
Results and discussion
Two male animals treated at 506 mg/kg died within the first hour after dosing and another animal was found dead two hours later. One animal treated at 320 mg/kg died during the first overnight period.
There was no death at the low dosage of 202 mg/kg.
Ante mortem signs comprised lethargy, underactivity, staggering gait, prone position, pallor, hyperpnoea, piloerection, hunched posture and pupil dilation.
Signs of reaction to treatment in the surviving animals in all dose levels included underactivity, staggering gait, piloerection, hunched posture and salivation. The majority of animals were overtly normal five days after dosing.
There was no sign of reaction to treatment in female animals.
Necropsy findings for the decedents were unremarkable. Necropsy of the surviving animals, on Day 15, revealed no significant macroscopic lesion.
The surviving animals achieved expected bodyweight gains.
♂ LD50 = 454 mg/kg (95% confidence limits 306, 601 mg/kg)
♀ The female animals treated at 202 mg/kg showed no sign of reaction to treatment, indicating the test material was not more toxic to female rats.- Executive summary:
Results and discussion
Two male animals treated at 506 mg/kg died within the first hour after dosing and another animal was found dead two hours later. One animal treated at 320 mg/kg died during the first overnight period.
There was no death at the low dosage of 202 mg/kg.
Ante mortem signs comprised lethargy, underactivity, staggering gait, prone position, pallor, hyperpnoea, piloerection, hunched posture and pupil dilation.
Signs of reaction to treatment in the surviving animals in all dose levels included underactivity, staggering gait, piloerection, hunched posture and salivation. The majority of animals were overtly normal five days after dosing.
There was no sign of reaction to treatment in female animals.
Necropsy findings for the decedents were unremarkable. Necropsy of the surviving animals, on Day 15, revealed no significant macroscopic lesion.
The surviving animals achieved expected bodyweight gains.
♂ LD50 = 454 mg/kg (95% confidence limits 306, 601 mg/kg)
♀ The female animals treated at 202 mg/kg showed no sign of reaction to treatment, indicating the test material was not more toxic to female rats.
Referenceopen allclose all
The acute oral median lethal dose value was 670 mg/kg (approximate 95% confidence limits 500, 900) to male rats and 784 mg/kg (lower 95% confidence limit 475) to female rats.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 490 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- yes
- Specific details on test material used for the study:
- Batch number: GK 100 B
- Species:
- rat
- Strain:
- other: CD strain (remote Sprague-Dawley origin)
- Sex:
- male/female
- Type of coverage:
- occlusive
- Vehicle:
- water
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Details on study design:
- The acute percutaneous toxicity of BIT was investigated in a group of five male and five female CD rats. The test material was applied to the closely-clipped dorsum of each animal at a dosage of 2000 mg/kg bodyweight and was covered by an occlusive dressing for 24 hours. Mortality, systemic and local signs of reaction to treatment were recorded during a subsequent 14-day period of observation. The animals were killed on the following day and subjected to necropsy.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There was no death and there were no systemic signs of reaction to treatment.
- Clinical signs:
- other: Local signs comprised very slight or well-defined erythema, slight exfoliation and eschar formation.
- Gross pathology:
- necropsy revealed no significant macroscopic lesion.
- Conclusions:
- There was no death and there were no systemic signs of reaction to treatment.
Local signs comprised very slight or well-defined erythema, slight exfoliation and eschar formation.
The animals achieved expected bodyweight gains and necropsy revealed no significant macroscopic lesion.
Accordingly, BIT was assigned to the class ‘low percutaneous toxicity’. - Executive summary:
A study was conducted to determine the acute dermal toxicity of the substance in rats according to OECD Guideline 402. The test substance was applied to the closely-clipped dorsum of a group of five male and five female rats at a dosage of 2000 mg/kg bodyweight and was covered by an occlusive dressing for 24 hours. Mortality, systemic and local signs of reaction to treatment were recorded during a subsequent 14-day period of observation. The animals were sacrificed on Day 15 and subjected to necropsy. There was no mortality and no systemic signs of reaction to treatment. Local signs comprised of very slight or well-defined erythema, slight exfoliation and eschar formation. The animals achieved expected bodyweight gains and necropsy revealed no significant macroscopic lesion. Under the study conditions, the acute dermal LD50 of the substance in rats was determined to be greater than 2000 mg/kg bw (Rees, 1994).
Reference
Under the conditions of this study, the acute percutaneous median lethal dosage (LD50) of the test material was greater than 2000 mg/kg.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Oral:
A study was conducted to determine the acute oral toxicity of the substance according to a method similar to OECD Guideline 401. Groups of five male and five female rats were administered a single oral dose of 0, 100, 300, 500 or 900 mg/kg bw of the substance in a 0.5% (w/v) aqueous polysorbate 80 suspension. The animals were weighed and observed for fourteen days after dosing. There was no mortality at 100 and 300 mg/kg. One female at 500 mg/kg bw was sacrificed in extremis. At 900 mg/kg bw there were signs of marked toxicity and all the males and three females died or were sacrificed in extremis on Day 1 or 2. There were no macroscopic abnormalities in any animal at necropsy. Under the study conditions, the acute oral LD50 of the substance was determined to be 670 mg/kg bw (490 mg a.i./kg bw) in rats (Leah, 1988).
Dermal:
A study was conducted to determine the acute dermal toxicity of the substance in rats according to OECD Guideline 402. The test substance was applied to the closely-clipped dorsum of a group of five male and five female rats at a dosage of 2000 mg/kg bodyweight and was covered by an occlusive dressing for 24 hours. Mortality, systemic and local signs of reaction to treatment were recorded during a subsequent 14-day period of observation. The animals were sacrificed on Day 15 and subjected to necropsy. There was no mortality and no systemic signs of reaction to treatment. Local signs comprised of very slight or well-defined erythema, slight exfoliation and eschar formation. The animals achieved expected bodyweight gains and necropsy revealed no significant macroscopic lesion. Under the study conditions, the acute dermal LD50 of the substance in rats was determined to be greater than 2000 mg/kg bw (Rees, 1994).
A study was conducted to determine the acute dermal toxicity of the substance in rats according to US EPA Guideline OPP 81 -2. The test substance was applied to the closely-clipped dorsum of a group of five male and five female rats at a dosage of 2000 mg/kg bodyweight and was covered by an occlusive dressing for 24 hours. Mortality, systemic and local signs of reaction to treatment were recorded during a subsequent 14-day period of observation. The animals were sacrificed on Day 15 and subjected to necropsy. There was no mortality and no systemic signs of reaction to treatment. Local signs of slight skin irritation were observed which persisted throughout the study. Under the study conditions, the acute dermal LD50 of the substance in rats was determined to be greater than 2000 mg/kg bw (Leah, 1988).
Justification for classification or non-classification
Based on the acute oral, inhalation and dermal toxicity studies with the substance, a classification as Acute Tox 4 (H302 -Harmful if swallowed) is warranted according to EU CLP (1272/2008) criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.